Moderna, Merck unveil mRNA-based cancer vaccine that cuts spread

VERBATIM fragments (each capped at 125 chars by the fetch tool; joins flagged).

- Lead (reassembled verbatim fragments; do not re-ground the joins): "Moderna and Merck have announced that" + "a personalised mRNA cancer vaccine called Intismeran" + "reduced the risk of recurrence and spread of melanoma in a late-stage trial" + "a major success in a new field of cancer treatment" + "sent Moderna's shares surging as much as 160 percent." (Note: Al Jazeera writes "160 percent", where Reuters/Times of Israel write "160%".)
- "the treatment met both goals of reducing cancer recurrence and preventing the spread of tumours"
- "Detailed results of the study have not been released but are expected to be shared at an upcoming medical meeting."
- "thousands of patients who have had high-risk melanoma tumours removed in surgery could benefit by next year." (attributed to Moderna president Hoge)
- "The development is the first positive late-stage trial result for an mRNA cancer vaccine."
- Karen Knudsen, Parker Institute: "The positive hit here leads us into truly this next phase in immunotherapy"; "This is an auspicious start - this is where things begin."
- "there were more than 1.5 million people in the US living with melanoma in 2023."

AUDIT NOTE: Carries the explicit disclosure "Detailed results of the study have not been released." No overall-survival mention in retrieved fragments; no hazard ratio given. Published 19 Aug 2026. Subheadline (verbatim): "Moderna's mRNA vaccine Intismeran shows promise, reducing melanoma recurrence and spread in late-stage trials."